Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

DroneShield announces research and manufacturing expansion

LAPP Australia launches Harnessing Solutions division

SA small and medium-sized businesses offered a new round of energy grants

Suntory Oceania's $3bn beverage business launched in Qld

Bega Group to close peanut processing business

New GDM diagnosis recommendations welcomed

Denise Lyons is the new APNA President

Regulators step in as medicinal cannabis prescriptions soar

Healthcare provider harnesses potential of agentic automation

2025 HESTA Excellence Awards finalists announced

Bonfiglioli to debut new products at Foodtech Packtech

Talk from the top with Dr Jayani Chandrapala

Wine and grape sector review report has 14 recommendations

Ferrero to acquire WK Kellogg Co for US$3.1bn

AFGC's videos busting myths about processed food

Lonza bone marrow and cord blood mononuclear cells

Cayman Chemical Bio-Active Lipid I Screening Library (96-Well)

Echelon Biosciences ionisable lipids

BioStatus CyTRAK Orange fluorescent dye

Content from other channels on our network